View Older Stories View More Recent Stories

May 23, 2018 08:15AM Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
May 22, 2018 08:00AM Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 22, 2018 08:00AM Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 10, 2018 08:30AM Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
May 10, 2018 08:30AM Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
May 4, 2018 04:01PM Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
May 4, 2018 04:01PM Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
May 2, 2018 07:40AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
May 2, 2018 07:40AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
May 2, 2018 07:31AM Esperion Therapeutics (ESPR) Phase 3 Long-Term Safety Study of Bempedoic Acid Meets Primary Endpoint
May 2, 2018 07:30AM Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
May 2, 2018 07:30AM Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
Apr 13, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 13, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 27, 2018 07:32AM Esperion Therapeutics (ESPR) Reports Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to CSK9 Inhibitor
Mar 27, 2018 07:30AM Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
Mar 27, 2018 07:30AM Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
Mar 7, 2018 04:01PM Esperion to Participate in Fireside Chat at March 2018 Investor Conferences
Mar 7, 2018 04:01PM Esperion to Participate in Fireside Chat at March 2018 Investor Conferences
Mar 7, 2018 07:33AM Esperion Therapeutics (ESPR) Phase 3 Study of Bempedoic Acid Met its Primary Endpoint
Mar 7, 2018 07:30AM Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
Mar 7, 2018 07:30AM Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
Feb 23, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 23, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 20, 2018 07:30AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
Feb 20, 2018 07:30AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
Jan 3, 2018 04:30PM Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
Jan 3, 2018 04:30PM Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
Dec 14, 2017 04:34PM Esperion Therapeutics (ESPR) Appoints Jeffrey Berkowitz to Board
Dec 14, 2017 04:30PM Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
Dec 14, 2017 04:30PM Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
Dec 1, 2017 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 13, 2017 04:30PM Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference
Nov 9, 2017 04:30PM Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
Nov 7, 2017 08:00AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
Nov 6, 2017 04:44PM Esperion Therapeutics (ESPR) Commences Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
Nov 6, 2017 04:30PM Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
Oct 10, 2017 08:30AM Esperion to Host Analyst and Investor Day Event on October 17
Oct 2, 2017 04:32PM Esperion Therapeutics (ESPR) Completes Enrollment in Phase 3 Program for Bempedoic Acid
Oct 2, 2017 04:30PM Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
Aug 11, 2017 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 8, 2017 08:00AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
Aug 8, 2017 07:39AM Esperion Therapeutics (ESPR) Says Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin Met Primary Endpoint
Aug 8, 2017 07:30AM Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
Aug 2, 2017 04:30PM Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results
Jul 26, 2017 04:41PM Esperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
Jul 26, 2017 04:30PM Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
Jun 26, 2017 04:06PM Esperion Therapeutics (ESPR) Reports FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid & Ezetimibe
Jun 26, 2017 04:05PM Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
Jun 14, 2017 04:30PM Esperion to Present at the JMP Securities 2017 Life Sciences Conference
View More Recent Stories View Older Stories